KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 120 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $258,000 | -35.8% | 36,288 | -34.8% | 0.00% | -33.3% |
Q2 2017 | $402,000 | -10.7% | 55,639 | -27.5% | 0.01% | 0.0% |
Q4 2016 | $450,000 | -12.8% | 76,726 | -1.6% | 0.01% | 0.0% |
Q2 2016 | $516,000 | +333.6% | 77,976 | +206.3% | 0.01% | +500.0% |
Q1 2016 | $119,000 | – | 25,457 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management, LLC | 700,273 | $10,770,000 | 5.76% |
HARVEY CAPITAL MANAGEMENT INC | 932,400 | $14,340,000 | 5.13% |
Camber Capital Management LP | 3,000,000 | $46,140,000 | 3.02% |
Baupost Group | 10,539,986 | $162,105,000 | 2.64% |
SECTORAL ASSET MANAGEMENT INC | 3,741,656 | $57,547,000 | 2.44% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,884,409 | $59,742,000 | 2.40% |
Knoll Capital Management, LLC | 200,000 | $3,076,000 | 1.37% |
DAFNA Capital Management LLC | 92,400 | $1,421,000 | 1.35% |
NORTHPOINTE CAPITAL LLC | 892,011 | $13,719,000 | 1.32% |
Rhenman & Partners Asset Management AB | 240,000 | $3,691,000 | 1.10% |